Drug research

Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514	Actinium Pharmaceuticals	Phase 2, Phase 3	Not yet recruiting	2029-02Estimated

Actinium PharmaceuticalsNot yet recruitingPrimary completion: 2029-02 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.